NATIONAL NHL TUMOR BOARD

Clinical Investigators Provide Their Perspectives on Cases of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Featuring Edited Proceedings and Interviews from a Case-Based Symposium Preceding the 52nd ASH Annual Meeting

Faculty
Myron S Czuczman, MD
Jonathan W Friedberg, MD, MMSc
David G Maloney, MD, PhD
Mathias J Rummel, MD, PhD
Mitchell R Smith, MD, PhD

Co-Chair
Stephanie A Gregory, MD

Moderator and Chair
Neil Love, MD

From the publishers of:

Hematologic Oncology UPDATE

Subscribe to Podcasts or download MP3s of this program at ResearchToPractice.com/ASHTB11
National NHL Tumor Board: Clinical Investigators Provide Their Perspectives on Cases of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
A Continuing Medical Education Program

OVERVIEW OF ACTIVITY
The treatment of hematologic cancer remains a challenge for many healthcare professionals and patients, despite recent gains made in the management of this group of diseases. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise and available health system resources. To bridge the gap between research and patient care, these proceedings from a case-based CME satellite symposium at the 2010 American Society of Hematology meeting use the perspectives of clinical investigators, in addition to the exchange among these individuals, to apply evidence-based concepts to routine practice. By providing information on the latest research developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies for hematologic cancer.

LEARNING OBJECTIVES
• Appraise recent data on therapeutic advances and changing practice standards in non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL), and integrate this information into current clinical care when appropriate.
• Apply the results of emerging clinical research to the selection of optimal systemic therapy for patients with newly diagnosed and relapsed or refractory CLL.
• Develop an algorithm for the risk-stratified induction treatment of diffuse large B-cell lymphoma (DLBCL) and mantle-cell lymphoma (MCL), and offer evidence-based systemic alternatives at the time of disease relapse.
• Identify patients with NHL who may experience quantitative and qualitative benefit from stem cell transplantation.
• Employ case-based learning to individualize the use of maintenance and/or consolidation therapy in the management of newly diagnosed and relapsed follicular lymphoma (FL).
• Recall the emerging data for novel agents and combinations in the treatment of NHL.
• Counsel appropriately selected patients about participation in ongoing clinical research studies.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY
This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the CDs and complete the Post-test and Educational Assessment and Credit Form located in the back of this booklet or on our website at ResearchToPractice.com/ASHTB11/CME.

This program is supported by educational grants from Cephalon Inc, Genentech BioOncology/Biogen Idec and Millennium — The Takeda Oncology Company.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Last review date: May 2011; Release date: May 2011; Expiration date: May 2012

If you would like to discontinue your complimentary subscription to Hematologic Oncology Update, please email us at Info@ResearchToPractice.com, call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.
CO-CHAIR

Stephanie A Gregory, MD
The Elodia Kehm Chair of Hematology; Professor of Medicine Director, Section of Hematology Rush University Medical Center/ Rush University Chicago, Illinois

FACULTY

Myron S Czuczman, MD
Head, Lymphoma/Myeloma Service Head, Lymphoma Translational Research Laboratory, Roswell Park Cancer Institute; Professor of Medicine, School of Medicine and Biomedical Sciences, State University of New York at Buffalo Buffalo, New York

Jonathan W Friedberg, MD, MMSc
Associate Professor of Medicine and Hematology Chief, Hematology/Oncology Division James P Wilmot Cancer Center University of Rochester Rochester, New York

David G Maloney, MD, PhD
Member, Clinical Research Division Fred Hutchinson Cancer Research Center; Professor of Medicine Division of Oncology University of Washington Seattle, Washington

Mathias J Rummel, MD, PhD
Head, Department for Hematology Hospital of the Justus-Liebig University Gießen, Germany

Mitchell R Smith, MD, PhD
Director, Lymphoma Service Fox Chase Cancer Center Philadelphia, Pennsylvania

MODERATOR AND CHAIR

Neil Love, MD
Research To Practice Miami, Florida

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

**Dr Czuczman** — Advisory Committee (AC): Amgen Inc, Biogen Idec, Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Millennium — The Takeda Oncology Company, Novartis Pharmaceuticals Corporation; Lectures: Biogen Idec, Genentech BioOncology.

**Dr Friedberg** — AC: Genentech BioOncology; Consulting Agreements (CA): Allos Therapeutics, Astellas Pharma US Inc, Calistoga Pharmaceuticals Inc, EMD Serono Inc, Seattle Genetics; Data Safety Monitoring Board: Lilly USA LLC; Research Support: Cephalon Inc, Millennium — The Takeda Oncology Company; Stock Ownership: Bristol-Myers Squibb Company.

**Dr Gregory** — AC: Cephalon Inc; CA: Amgen Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Spectrum Pharmaceuticals Inc; Speakers Bureau (SB): Cephalon Inc, Genentech BioOncology.

**Dr Maloney** — AC: Genentech BioOncology, GlaxoSmithKline, Roche Laboratories Inc, Spectrum Pharmaceuticals Inc.

**Dr Rummel** — AC: Amgen Inc, Cephalon Inc, GlaxoSmithKline.

**Dr Smith** — AC: Cephalon Inc, Wyeth; SB: Allos Therapeutics, Celgene Corporation, Cephalon Inc, Genentech BioOncology, Millennium — The Takeda Oncology Company.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium — The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
1. GA101 is a humanized anti-CD20 monoclonal antibody being compared head to head to rituximab for patients with CD20-positive DLBCL.
   a. True
   b. False

2. Which of the following has been shown in the PRIMA trial with two years of maintenance rituximab compared to observation in FL?
   a. Improvement in progression-free survival
   b. Improvement in overall survival
   c. Both a and b
   d. None of the above

3. In the PRIMA trial, maintenance rituximab 375 mg/m² was administered every ________ for two years.
   a. Month
   b. Two months
   c. Three months
   d. Four months

4. SWOG-S0016 is an ongoing trial of consolidation radioimmunotherapy (RIT) in FL that will compare R-CHOP to ________.
   a. R-CHOP followed by maintenance rituximab
   b. R-CHOP followed by RIT
   c. CHOP followed by RIT

5. In the FIT trial, patients with FL who received consolidation RIT had a chance of developing myelodysplastic syndromes in the first five years.
   a. Zero percent
   b. Three percent
   c. 10 percent

6. An improvement in overall survival has been reported for bendamustine/rituximab (BR) compared to R-CHOP as up-front treatment for FL.
   a. True
   b. False

7. In the study of up-front BR versus R-CHOP, no difference was observed between the two arms in the ability to mobilize and collect stem cells in select younger patients with FL.
   a. True
   b. False

8. At ASH 2009, a study suggested that substituting doxorubicin (R-CHOP) with etoposide (R-CEOP) resulted in good outcomes in patients with DLBCL who had contraindications to anthracyclines.
   a. True
   b. False

9. Which of the following are true about HIV-associated NHL?
   a. CD4 counts are prognostic
   b. Patients with higher CD4 counts tolerate treatment better
   c. More patients are able to undergo autologous stem cell transplant after relapse in the era of combined antiretroviral therapy
   d. All of the above

10. The presence of 17p deletion in CLL is considered a ____________.
    a. Positive prognostic factor
    b. Negative prognostic factor
    c. Neither; 17p deletion has not been shown to affect outcome

11. Treatment of CLL with alemtuzumab should be accompanied by prophylaxis against which of the following?
    a. Pneumocystis pneumonia
    b. Herpes virus
    c. Both a and b
    d. Neither a nor b

12. A randomized trial presented at ASH 2010 by the European Mantle Cell Lymphoma Network demonstrated that the addition of high-dose Ara-C (cytarabine) does not affect treatment outcomes in younger patients with MCL.
    a. True
    b. False

Post-test answer key: 1a, 2a, 3b, 4c, 5b, 6b, 7a, 8a, 9d, 10b, 11c, 12b
EDUCATIONAL ASSESSMENT AND CREDIT FORM

National NHL Tumor Board: Clinical Investigators Provide Their Perspectives on Cases of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

PART ONE — Please tell us about your experience with this educational activity

How would you characterize your level of knowledge on the following topics?

<table>
<thead>
<tr>
<th></th>
<th>BEFORE</th>
<th>AFTER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose and schedule of BR for DLBCL</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>PRIMA study of maintenance rituximab for patients with high tumor burden FL responding to chemotherapy/rituximab</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Consolidation radioimmunotherapy or stem cell transplant in FL</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
</tbody>
</table>

Was the activity evidence based, fair, balanced and free from commercial bias?

☐ Yes  ☐ No

If no, please explain:

Please identify how you will change your practice as a result of completing this activity (select all that apply).

☐ This activity validated my current practice; no changes will be made
☐ Create/revise protocols, policies and/or procedures
☐ Change the management and/or treatment of my patients
☐ Other (please explain):

If you intend to implement any changes in your practice, please provide one or more examples:

The content of this activity matched my current (or potential) scope of practice.

☐ Yes  ☐ No

If no, please explain:

Please respond to the following learning objectives (LOs) by circling the appropriate selection:

4 = Yes  3 = Will consider  2 = No  1 = Already doing  N/M = LO not met  N/A = Not applicable

As a result of this activity, I will be able to:

• Appraise recent data on therapeutic advances and changing practice standards in non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL), and integrate this information into current clinical care when appropriate.  4 3 2 1 N/M N/A
• Apply the results of emerging clinical research to the selection of optimal systemic therapy for patients with newly diagnosed and relapsed or refractory CLL.  4 3 2 1 N/M N/A
• Develop an algorithm for the risk-stratified induction treatment of diffuse large B-cell lymphoma (DLBCL) and mantle-cell lymphoma (MCL), and offer evidence-based systemic alternatives at the time of disease relapse.  4 3 2 1 N/M N/A
• Identify patients with NHL who may experience quantitative and qualitative benefit from stem cell transplantation.  4 3 2 1 N/M N/A
• Employ case-based learning to individualize the use of maintenance and/or consolidation therapy in the management of newly diagnosed and relapsed follicular lymphoma (FL).  4 3 2 1 N/M N/A
• Recall the emerging data for novel agents and combinations in the treatment of NHL.  4 3 2 1 N/M N/A
• Counsel appropriately selected patients about participation in ongoing clinical research studies.  4 3 2 1 N/M N/A
EDUCATIONAL ASSESSMENT AND CREDIT FORM (continued)

Please describe any clinical situations that you find difficult to manage or resolve that you would like to see addressed in future educational activities:

Would you recommend this activity to a colleague?
☐ Yes  ☐ No
If no, please explain:

Additional comments about this activity:

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey.
☐ Yes, I am willing to participate in a follow-up survey.
☐ No, I am not willing to participate in a follow-up survey.

PART TWO — Please tell us about the faculty and moderator for this educational activity

<table>
<thead>
<tr>
<th>Faculty</th>
<th>Knowledge of subject matter</th>
<th>Effectiveness as an educator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myron S Czuczzman, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Jonathan W Friedberg, MD, MMSc</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Stephanie A Gregory, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>David G Maloney, MD, PhD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Mathias J Rummel, MD, PhD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Mitchell R Smith, MD, PhD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Moderator</th>
<th>Knowledge of subject matter</th>
<th>Effectiveness as an educator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neil Love, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
</tbody>
</table>

Please recommend additional faculty for future activities:

Other comments about the faculty and moderator for this activity:

REQUEST FOR CREDIT — Please print clearly

Name: .......................................................... Specialty: ..........................................................

Professional Designation:
☐ MD  ☐ DO  ☐ PharmD  ☐ NP  ☐ RN  ☐ PA  ☐ Other ..........................................................

Street Address: .......................................................... Box/Suite: ..........................................................

City, State, Zip: ..........................................................

Telephone: .......................................................... Fax: ..........................................................

Email: ..........................................................

Research To Practice designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

I certify my actual time spent to complete this educational activity to be _________ hour(s).

Signature: .......................................................... Date: ..........................................................

To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at www.ResearchToPractice.com/ASHTB11/CME.